Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Go back to Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 116.83 +1.04 (0.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.79 | 52 Week High | $118.49 | |||
| Open | $115.04 | 52 Week Low | $55.00 | |||
| Day High | $117.47 | P/E | N/A | |||
| Day Low | $114.51 | EPS | $-0.56 | |||
| Volume | 498,590 | |||||
